Mucopolysaccharidosis Treatment Market Report 2026

The mucopolysaccharidosis treatment market size has grown strongly in recent years. It will grow from $2.58 billion in 2025 to $2.78 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to limited awareness of mps disorders, high treatment costs, slow adoption of enzyme therapy, restricted clinical trial availability, reliance on international drug supply.

The mucopolysaccharidosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.79 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to expansion of gene therapy research, increasing healthcare investments, improved rare disease screening programs, broader reimbursement coverage, growth in precision medicine platforms. Major trends in the forecast period include advancements in enzyme replacement therapy, growing adoption of stem cell transplantation, increasing development of gene therapy approaches, rising focus on early diagnosis and newborn screening, expansion of specialized treatment centers.

The rising prevalence of mucopolysaccharidosis (MPS) is expected to drive the growth of the mucopolysaccharidosis treatment market in the coming years. MPS is a group of rare genetic disorders caused by deficiencies in specific enzymes, leading to the accumulation of complex carbohydrates called glycosaminoglycans (GAGs) in bodily tissues. Treatments for MPS aim to reduce GAG accumulation, manage symptoms, and prevent complications through various therapeutic approaches. For instance, in July 2024, according to the Orphanet Journal of Rare Diseases, a France-based peer-reviewed open-access medical journal, the incidence of MPS IVa is estimated at approximately 1 in 201,000 live births, while MPS VI prevalence ranges between 1 in 43,261 and 1 in 1,505,160 depending on the population. Therefore, the rising prevalence of MPS is propelling the market for its treatment.

Major companies in the mucopolysaccharidosis treatment market are focusing on innovative therapies such as AAV gene therapies to address the underlying genetic causes and provide long-term correction of neurological deficits. Adeno-associated viral (AAV) gene therapy delivers functional genes into central nervous system cells to restore the production of missing or deficient proteins. For example, in August 2025, REGENXBIO Inc., a US-based biotechnology company, reported that the US FDA extended its review of RGX-121 following the submission of long-term clinical data, confirming consistent biomarker and neurodevelopmental outcomes. Regulatory progress and clean pre-license inspections indicate strong potential for RGX-121 to become the first one-time therapy targeting neurological manifestations of MPS II.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics, a UK-based biotech company specializing in mucopolysaccharidosis treatment, for an undisclosed amount. This acquisition combines Kyowa Kirin’s biopharmaceutical expertise with Orchard’s gene therapy platform, strengthening their capabilities in delivering transformative therapies for severe genetic disorders.

Major companies operating in the mucopolysaccharidosis treatment market are BioMarin Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Abeona Therapeutics Inc., Immusoft Corporation, Neurogene Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Denali Therapeutics Inc., Passage Bio Inc., Homology Medicines Inc., AVROBIO Inc., Rocket Pharmaceuticals Inc., Taysha Gene Therapies Inc., Freeline Therapeutics Holdings plc, 4D Molecular Therapeutics Inc., Sio Gene Therapies Inc., SpliceBio S.L., LogicBio Therapeutics Inc., Orchard Therapeutics plc, Asklepios BioPharmaceutical Inc.

North America was the largest region in the mucopolysaccharidosis treatment market in 2025. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mucopolysaccharidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs in the mucopolysaccharidosis treatment market have increased the cost of importing enzyme replacement therapy drugs, infusion devices, and specialized biologics manufacturing components. Hospitals and specialty clinics in regions dependent on imported MPS therapies face higher treatment expenses and longer procurement timelines. However, tariffs have also stimulated interest in local manufacturing and regional biopharma development, creating long-term opportunities to reduce reliance on global suppliers.

The mucopolysaccharidosis treatment market research report is one of a series of new reports that provides mucopolysaccharidosis treatment market statistics, including mucopolysaccharidosis treatment industry global market size, regional shares, competitors with a mucopolysaccharidosis treatment market share, detailed mucopolysaccharidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mucopolysaccharidosis treatment industry. This mucopolysaccharidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mucopolysaccharidosis (MPS) treatment involves therapies for hereditary disorders in which the body is unable to break down glycosaminoglycans (long sugar chains) due to the absence or malfunction of specific enzymes. This condition is commonly caused by a deficiency or dysfunction of a particular lysosomal enzyme.

The main types of mucopolysaccharidosis treatments include enzyme replacement therapy and stem cell therapy. Enzyme replacement therapy is a medical procedure in which patients with chronic diseases caused by enzyme deficiency or dysfunction receive replacement enzymes. This therapy is applied for conditions such as mucopolysaccharidosis I, II, IV, VI, and others. Treatments are administered via intravenous or intracerebroventricular routes and are used by various end users, including hospitals, specialty clinics, and others.

The mucopolysaccharides treatment market includes revenues earned by entities by providing medication services such as enzyme replacement therapy, stem cell transplantation, gene therapy, substrate reduction therapy, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.